Posted by Michael Wonder on 20 Apr 2023
Rybrevant (amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations
6 April 2023 - This CADTH recommendation is a step towards public access to Rybrevant as a targeted therapy for an underserved patient population.
Janssen today announced that CADTH has recommended Rybrevant (amivantamab) for public reimbursement in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
